The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Abstract
BACKGROUND: No safe and convenient regimen has proved to be effective for the management of recurrent vulvovaginal candidiasis. METHODS: After inducing clinical remission with open-label fluconazole given in three 150-mg doses at 72-hour intervals, we randomly assigned 387 women with recurrent vulvovaginal candidiasis to receive treatment with fluconazole (150 mg) or placebo weekly for six months, followed by six months of observation without therapy. The primary outcome measure was the proportion of women in clinical remission at the end of the first six-month period. Secondary efficacy measures were the clinical outcome at 12 months, vaginal mycologic status, and time to recurrence on the basis of Kaplan-Meier analysis. RESULTS: Weekly treatment with fluconazole was effective in preventing symptomatic vulvovaginal candidiasis. The proportions of women who remained disease-free at 6, 9, and 12 months in the fluconazole group were 90.8 percent, 73.2 percent, and 42.9 percent, as compared with 35.9 percent, 27.8 percent, and 21.9 percent, respectively, in the placebo group (P< 0.001). The median time to clinical recurrence in the fluconazole group was 10.2 months, as compared with 4.0 months in the placebo group (P<0.001). There was no evidence of fluconazole resistance in isolates of Candida albicans or of superinfection with C. glabrata. Fluconazole was discontinued in one patient because of headache. CONCLUSIONS: Long-term weekly treatment with fluconazole can reduce the rate of recurrence of symptomatic vulvovaginal candidiasis. However, a long-term cure remains difficult to achieve.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although symptom resolution is achieved in ~90% of women with RVVC who undergo ⩾6 months of maintenance therapy,16,21,22 up to 50% will have a recurrence after the termination of maintenance therapy. 13”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [21]
In the citing paper
“A landmark RVVC treatment study using an induction regimen of fluconazole (three 150 mg doses at 72 h intervals) followed by weekly maintenance doses of 150 mg of fluconazole for 6 months was shown to reduce symptoms and recurrences. 21”
From Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis (2022) · cites this paper as [21]
In the citing paper
“The mainstay of treatment for most cases of uncomplicated VVC is azole antifungals, which, by inhibiting the fungal enzyme CYP51, prevent the accumulation of fungitoxic sterols [11,34].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [34]
In the citing paper
“During the treatment phases, relapse rates vary between 21% (Donders et al., 2008a), 57.1% (Sobel et al., 2004), and 71.9% (Bolouri et al., 2009) at 12 months depending upon the characteristics of the therapeutic regimen used, as described in Supplementary Tables 2 and 3 .”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Likewise, other studies found that up to 50% of women with RVVC relapsed after stopping their maintenance therapy regimen (Sobel et al., 2004; Donders et al., 2008a) or that additional fluconazole therapy was continued for longer than 6 months due to either culture-confirmed VVC recurrence, microbiologically unconfirmed but clinically possible VVC recurrence, or due to patients’ preference to”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“With the regimen proposed by Sobel et al. (Sobel et al., 2004) (150 mg of oral fluconazole or placebo once a week for 6 months, after a successful induction phase), 42.9% of 387 women were still disease free at 12 months, indicating over half relapsed after maintenance therapy with fluconazole was stopped.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Median time to clinical and mycological relapse was 10.2 and 8.4 months, respectively.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“With the regimen proposed by Sobel et al. (Sobel et al., 2004) (150 mg of oral fluconazole or placebo once a week for 6 months, after a successful induction phase), 42.9% of 387 women were still disease free at 12 months, indicating over half relapsed after maintenance therapy with fluconazole was stopped.”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
In the citing paper
“Although oral fluconazole is highly effective at reducing acute episodes during maintenance therapy, long-term remission after stopping the regimen is only present in about half of patients (Sobel et al., 2004; Donders et al., 2008a).”
From Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion (2022) · cites this paper as Sobel et al., 2004
Citations
Cites
Hepatic Injury Associated With Ketoconazole Therapy
Lewis, J. H., Zimmerman, H. J., Benson, G. D., & Ishak, K. G. (1984) · Gastroenterology · doi:10.1016/s0016-5085(84)80021-9 · Cited by 392
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis
Sobel, J. D. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(85)80003-x · Cited by 332
Self-citationImmunopathogenesis of recurrent vulvovaginal candidiasis
Fidel, P. L., & Sobel, J. D. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.335 · Cited by 298
Self-citationRecurrent Vulvovaginal Candidiasis
Sobel, J. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612043152305 · Cited by 219
Self-citationCandida vaginitis: Self-Reported Incidence and Associated Costs
Foxman, B., Barlow, R., Dʼarcy, H., Gillespie, B., & Sobel, J. D. (2000) · Sexually Transmitted Diseases · doi:10.1097/00007435-200004000-00009 · Cited by 158
Self-citationWeekly Fluconazole for the Prevention of Mucosal Candidiasis in Women with HIV Infection
Schuman, P. C., Capps, L., Peng, G., Vazquez, J., El-Sadr, W. M., Goldman, A. I., Alston, B., Besch, C. L., Vaughn, A., Thompson, M., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-9-199705010-00003 · Cited by 120
Self-citationFoxman, B., MARSH, J. V., Gillespie, B. W., & Sobel, J. D. (1998) · Journal of Women s Health · doi:10.1089/jwh.1998.7.1167 · Cited by 92
Self-citationHouang, E. T., Chappatte, O., Byrne, D., Macrae, P. V., & Thorpe, J. E. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.5.909 · Cited by 76
Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis
Spinillo, A., Pizzoli, G., Colonna, L., Nicola, S., Seta, F. D., & Guaschino, S. (1994) · International Journal of Gynecology & Obstetrics · doi:10.1016/0020-7292(94)90096-5 · Cited by 72
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis.
Sobel, J. D. (1985) · PubMed · Cited by 62
Self-citation
Cited by
Sorted by citations
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Self-citationCandida Infections of the Genitourinary Tract
Achkar, J. M., & Fries, B. C. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00076-09 · Cited by 736
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors
Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669
Recurrent vulvovaginal candidiasis
Sobel, J. D. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.06.067 · Cited by 502
Self-citationRichter, S. S., Galask, R. P., Messer, S. A., Hollis, R. J., Diekema, D. J., & Pfaller, M. A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.5.2155-2162.2005 · Cited by 435
Vulvovaginal Candidiasis: A Current Understanding and Burning Questions
Willems, H. M. E., Ahmed, S. S., Liu, J., Xu, Z., & Peters, B. M. (2020) · Journal of Fungi · doi:10.3390/jof6010027 · Cited by 357
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Sherrard, J., Wilson, J., Donders, G., Mendling, W., & Jensen, J. S. (2018) · International Journal of STD & AIDS · doi:10.1177/0956462418785451 · Cited by 297
An update on antifungal targets and mechanisms of resistance in Candidaalbicans
Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291
Forgotten fungi—the gut mycobiome in human health and disease
Huseyin, C. E., O’Toole, P. W., Cotter, P. D., & Scanlan, P. D. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuw047 · Cited by 284
Yano, J., Sobel, J. D., Nyirjesy, P., Sobel, R., Williams, V. L., Yu, Q., Noverr, M. C., & Fidel, P. L. (2019) · BMC Women's Health · doi:10.1186/s12905-019-0748-8 · Cited by 270
Self-citationSchmidt, C. S., White, C. J., Ibrahim, A. S., Filler, S. G., Fu, Y., Yeaman, M. R., Edwards, J. E., & Hennessey, J. P. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.038 · Cited by 233
Edwards, J. E., Schwartz, M. M., Schmidt, C. S., Sobel, J. D., Nyirjesy, P., Schodel, F., Marchus, E., Lizakowski, M., DeMontigny, E. A., Hoeg, J., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy185 · Cited by 213
Self-citationBitew, A., & Abebaw, Y. (2018) · BMC Women s Health · doi:10.1186/s12905-018-0607-z · Cited by 212
Recurrent Vulvovaginal Candidiasis: An Immunological Perspective
Rosati, D., Bruno, M., Jaeger, M., ten Oever, J., & Netea, M. G. (2020) · Microorganisms · doi:10.3390/microorganisms8020144 · Cited by 206
Vulvovaginal C andida albicans infections: pathogenesis, immunity and vaccine prospects
Cassone, A. (2014) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.12994 · Cited by 206
Fluconazole-Resistant Candida albicans Vulvovaginitis
Marchaim, D., Lemanek, L., Bheemreddy, S., Kaye, K. S., & Sobel, J. D. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31827307b2 · Cited by 195
Self-citationvan Schalkwyk, J., Yudin, M. H., Yudin, M. H., Allen, V. M., Bouchard, C., Boucher, M., Boucoiran, I., Caddy, S. C., Castillo, E., Kennedy, V. L., et al. (2015) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30316-9 · Cited by 187
Guideline: Vulvovaginal Candidosis (AWMF 015/072, Level S2k)
Farr, A., Effendy, I., Frey Tirri, B., Hof, H., Mayser, P., Petricevic, L., Ruhnke, M., Schaller, M., Schaefer, A. P. A., Sustr, V., et al. (2021) · Mycoses · doi:10.1111/myc.13248 · Cited by 184
An Update on the Roles of Non-albicans Candida Species in Vulvovaginitis
Makanjuola, O., Bongomin, F., & Fayemiwo, S. (2018) · Journal of Fungi · doi:10.3390/jof4040121 · Cited by 182
Wijeysundera, D. N., Austin, P. C., Hux, J. E., Beattie, W. S., & Laupacis, A. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.07.006 · Cited by 188
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168
Self-citationVulvovaginal Candidiasis in Pregnancy
Aguin, T., & Sobel, J. D. (2015) · Current Infectious Disease Reports · doi:10.1007/s11908-015-0462-0 · Cited by 166
Self-citationKaufman, D. A., Boyle, R. J., Hazen, K. C., Patrie, J. T., Robinson, M. L., & Grossman, L. B. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.03.036 · Cited by 162
Advanced topical drug delivery system for the management of vaginal candidiasis
Johal, H. S., Garg, T., Rath, G., & Goyal, A. K. (2014) · Drug Delivery · doi:10.3109/10717544.2014.928760 · Cited by 158
Colombo, A. L., Guimarães, T., Camargo, L. F. A., Richtmann, R., Queiroz‐Telles, F., Salles, M. J. C., da Cunha, C. A., Shikanai‐Yasuda, M. A., Moretti, M. L., & Nucci, M. (2013) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2013.02.001 · Cited by 161
Lin, M., Carmeli, Y., Zumsteg, J. M., Flores, E., Tolentino, J., Sreeramoju, P., & Weber, S. G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4555-4560.2005 · Cited by 151
Vaginal pH Value for Clinical Diagnosis and Treatment of Common Vaginitis
Lin, Y.-P., Chen, W., Cheng, C., & Shen, C. (2021) · Diagnostics · doi:10.3390/diagnostics11111996 · Cited by 135
European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011
Sherrard, J., Donders, G. G. G., White, D., & Jensen, J. S. (2011) · International Journal of STD & AIDS · doi:10.1258/ijsa.2011.011012 · Cited by 136
Donders, G., Bellen, G., Byttebier, G., Verguts, L., Hinoul, P., Walckiers, R., Stalpaert, M., Vereecken, A., & Van Eldere, J. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.06.029 · Cited by 127
Aballéa, S., Guelfucci, F., Wagner, J., Khemiri, A., Dietz, J.-P., Sobel, J. D., & Toumi, M. (2013) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-11-169 · Cited by 131
Self-citationEckert, L. O. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp053720 · Cited by 126
Guideline: Vulvovaginal Candidosis (AWMF 015/072), S2k (Excluding Chronic Mucocutaneous Candidosis)
Mendling, W. (2015) · Mycoses · doi:10.1111/myc.12292 · Cited by 117
Mendling, W., & Brasch, J. (2012) · Mycoses · doi:10.1111/j.1439-0507.2012.02185.x · Cited by 110
Goswami, D., Goswami, R., Banerjee, U., Dadhwal, V., Miglani, S., Lattif, A. A., & Kochupillai, N. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.03.005 · Cited by 104
Paulitsch‐Fuchs, A. H., Weger, W., Ginter‐Hanselmayer, G., Marth, E., & Buzina, W. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01284.x · Cited by 102
Vaginitis in Nonpregnant Patients
(2019) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003604 · Cited by 103
Vulvovaginal Candidiasis and Bacterial Vaginosis
Nyirjesy, P. (2008) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.05.002 · Cited by 101
Pendharkar, S., Brandsborg, E., Hammarström, L. L. G., Marcotte, H., & Larsson, P. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0971-3 · Cited by 99
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response
Ibrahim, A. S., Luo, G., Gebremariam, T., Lee, H.-K., Schmidt, C. S., Hennessey, J. P., French, S. W., Yeaman, M. R., Filler, S. G., & Edwards, J. E. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.09.016 · Cited by 102
Genital Mycotic Infections in Patients With Diabetes
Nyirjesy, P., & Sobel, J. D. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2650 · Cited by 97
Self-citationMcClelland, R. S., Richardson, B. A., Hassan, W., Chohan, V., Lavreys, L., Mandaliya, K. N., Kiarie, J. N., Jaoko, W. G., Ndinya‐Achola, J. O., Baeten, J. M., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/587490 · Cited by 96
Russo, R., Superti, F., Karadja, E., & De Seta, F. (2019) · Mycoses · doi:10.1111/myc.12883 · Cited by 94
Faria, N. C. G., Kim, J. H., Gonçalves, L. A. P., Martins, M. D. L., Chan, K. L., & Campbell, B. C. (2011) · Letters in Applied Microbiology · doi:10.1111/j.1472-765x.2011.03032.x · Cited by 93
Recent advances in delivery of antifungal agents for therapeutic management of candidiasis
Sawant, B., & Khan, T. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.127 · Cited by 94
Prevalence & susceptibility to fluconazole of Candida species causing vulvovaginitis.
Mohanty, S., Xess, I., Hasan, F., Kapil, A., Mittal, S., & Tolosa, J. E. (2007) · PubMed · Cited by 91
McKinnell, J. A., Stollenwerk, N. S., Jung, C. W., & Miller, L. G. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0800 · Cited by 89
Zhu, Y.-X., Li, T., Fan, S.-R., Liu, X.-P., Liang, Y.-H., & Liu, P. (2016) · Health and Quality of Life Outcomes · doi:10.1186/s12955-016-0470-2 · Cited by 88
Donders, G. G. G., Babula, O., Bellen, G., Linhares, I. M., & Witkin, S. S. (2008) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2008.01830.x · Cited by 88
Pietrella, D., Rachini, A., Torosantucci, A., Chiani, P., Brown, A. J. P., Bistoni, F., Costantino, P., Mosci, P., d’Enfert, C., Rappuoli, R., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.12.021 · Cited by 89
Martens, M. G., Maximos, B., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., Flynt, A., & Brand, S. R. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2022.07.023 · Cited by 86
Self-citationTreatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84
Garvey, E. P., HOEKSTRA, W., Schotzinger, R. J., Sobel, J. D., Lilly, E. A., & Fidel, P. L. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00185-15 · Cited by 84
Self-citationManagement of Recurrent Vulvo-Vaginal Candidosis as a Chronic Illness
Donders, G. G. G., Bellen, G., & Mendling, W. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000314022 · Cited by 83
Bhattacharya, S., Sobel, J. D., & White, T. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01252-16 · Cited by 83
Self-citationDonders, G., Sziller, I. O., Paavonen, J., Hay, P., de Seta, F., Bohbot, J. M., Kotarski, J., Vives, J. A., Szabo, B., Cepuliené, R., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.934353 · Cited by 82
Gu, W., Guo, D., Zhang, L., Xu, D., & Sun, S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03046-15 · Cited by 80
Oteseconazole: An Advance in Treatment of Recurrent Vulvovaginal Candidiasis
Sobel, J. D., & Nyirjesy, P. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0173 · Cited by 78
Self-citationBrand, S. R., Degenhardt, T. P., Person, K., Sobel, J. D., Nyirjesy, P., Schotzinger, R. J., & Tavakkol, A. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.03.001 · Cited by 78
Self-citationTerpenoids with antifungal activity trigger mitochondrial dysfunction in Saccharomyces cerevisiae
Haque, E., Irfan, S., Kamil, M., Sheikh, S., Hasan, A., Ahmad, A., Lakshmi, V., Nazir, A., & Mir, S. S. (2016) · Microbiology · doi:10.1134/s0026261716040093 · Cited by 77
Powell, A. M., & Nyirjesy, P. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.07.006 · Cited by 74
Probiotics in the Prevention and Treatment of Postmenopausal Vaginal Infections: Review Article
Kim, J. M., & Park, Y. J. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.3.139 · Cited by 72
Candida vaginitis: virulence, host response and vaccine prospects
Bernardis, F. D., Graziani, S., Tirelli, F., & Antonopoulou, S. (2017) · Medical Mycology · doi:10.1093/mmy/myx139 · Cited by 72
Influence of recurrent vulvovaginal candidiasis on quality of life issues
Fukazawa, E. I., Witkin, S. S., Robial, R., Vinagre, J. G., Baracat, E. C., & Linhares, I. M. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05228-3 · Cited by 69
Vicariotto, F., Piano, M. D., Mogna, L., & Mogna, G. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3182684d71 · Cited by 69
Recurrent vulvovaginal candidiasis: A review of guideline recommendations
Matheson, A., & Mazza, D. (2017) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12592 · Cited by 68
Microsatellite Marker Analysis as a Typing System for Candida glabrata
Foulet, F., Nicolas, N., Eloy, O., Botterel, F., Gantier, J.-C., Costa, J., & Bretagne, S. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.9.4574-4579.2005 · Cited by 68
Watson, C. J., & Calabretto, H. (2007) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2007.00736.x · Cited by 65
Management of Persistent Vaginitis
Nyirjesy, P. (2014) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000551 · Cited by 63
Sardi, J. D. C. O., Silva, D. R., Aníbal, P. C., Baldin, J. J. C. M. D. C., Ramalho, S. R., Rosalen, P. L., Macedo, M. L. R., & Höfling, J. F. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00415-9 · Cited by 62
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis
Brand, S. R., Sobel, J. D., Nyirjesy, P., Ghannoum, M. A., Schotzinger, R. J., & Degenhardt, T. P. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1204 · Cited by 61
Self-citationSun, L., Sun, S., Cheng, A., Wu, X., Zhang, Y., & Lou, H. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00940-08 · Cited by 60
Choukri, F., Benderdouche, M., & Sednaoui, P. (2014) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2014.05.001 · Cited by 60
Anticandidal Immunity and Vaginitis: Novel Opportunities for Immune Intervention
Cassone, A., de Bernardis, F., & Santoni, G. (2007) · Infection and Immunity · doi:10.1128/iai.00083-07 · Cited by 58
LaFleur, M. D., Lucumi, E., Napper, A. D., Diamond, S. L., & Lewis, K. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq530 · Cited by 59
Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin Number 215
Paavonen, J. A., & Brunham, R. C. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003857 · Cited by 61
Zinc prevents vaginal candidiasis by inhibiting expression of an inflammatory fungal protein
Roselletti, E., Pericolini, E., Nore, A., Takács, P., Kozma, B., Sala, A., Seta, F. D., Comar, M., Usher, J., Brown, G. D., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi3363 · Cited by 58
Clinical challenges in diagnosis and treatment of recurrent vulvovaginal candidiasis
Neal, C. M., & Martens, M. G. (2022) · SAGE Open Medicine · doi:10.1177/20503121221115201 · Cited by 56
Self-citationBacterial Vaginosis and Vulvovaginal Candidiasis Pathophysiologic Interrelationship
Sobel, J. D., & Vempati, Y. S. (2024) · Microorganisms · doi:10.3390/microorganisms12010108 · Cited by 56
Self-citationMurina, F., Graziottin, A., Vicariotto, F., & Seta, F. D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000225 · Cited by 56
Eells, S. J., Bharadwa, K., McKinnell, J. A., & Miller, L. G. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit646 · Cited by 56
Collins, L. M., Moore, R., & Sobel, J. D. (2020) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000496 · Cited by 55
Self-citationEfficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Donders, G., Degenhardt, T., Person, K., Curelop, S., Ghannoum, M., & Brand, S. R. (2022) · NEJM Evidence · doi:10.1056/evidoa2100055 · Cited by 55
Self-citationShahid, Z., & Sobel, J. D. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.03.021 · Cited by 55
Self-citationColonization by Candida Species of the Oral and Vaginal Mucosa in HIV-Infected and Noninfected Women
Merenstein, D. J., Hu, H., Wang, C., Hamilton, P., Blackmon, M., Chen, H., Calderone, R., & Li, D. (2012) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2012.0269 · Cited by 54
Jaeger, M., Pinelli, M., Borghi, M., Costantini, C., Dindo, M., van Emst, L., Puccetti, M., Pariano, M., Ricaño-Ponce, I., Büll, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar3558 · Cited by 57
Self-citationLírio, J., Giraldo, P. C., Amaral, R. L., Sarmento, A. C. A., Costa, A. P. F., & Gonçalves, A. K. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027489 · Cited by 53
Chronic vulvovaginal candidiasis: What we know and what we have yet to learn
Fischer, G. O. (2012) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.2011.00860.x · Cited by 52
Friedman, M., Xu, A., Lee, R., Nguyen, D. N., Phan, T. A., Hamada, S. M., Panchel, R., Tam, C. C., Jong Heon, K. I. M., Cheng, L. W., et al. (2020) · Molecules · doi:10.3390/molecules25133101 · Cited by 52
Mendonca, P., Capoci, I. R. G., Tobaldini-Valério, F. K., Negri, M., & Svidzinski, T. I. E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091629 · Cited by 51
McClelland, R. S., Balkus, J. E., Lee, J. Y., Anzala, O. A., Kimani, J., Schwebke, J. R., Bragg, V., Lensing, S., & Kavak, L. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu818 · Cited by 51
da Rosa, M. I., Silva, B. R., Pires, P. S., Silva, F. R., Silva, N. C., Silva, F. R., Souza, S. L., Madeira, K., Panatto, A. P. R., & Medeiros, L. R. (2012) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2012.12.001 · Cited by 51
Theill, L., Dudiuk, C., Morano, S., Gamarra, S. P., Nardin, M. E., Méndez, E., & García‐Effrón, G. (2016) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2015.10.003 · Cited by 51
Species spectrum and antifungal susceptibility profile of vaginal isolates of Candida in Kuwait
Alfouzan, W. A., Dhar, R., Ashkanani, H., Gupta, M., Rachel, C., & Khan, Z. (2014) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2014.10.021 · Cited by 50
Vaginitis: Diagnosis and Management
Quan, M. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.11.2229 · Cited by 50
Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis
Sobel, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s38984 · Cited by 48
Self-citationTreatment for recurrent vulvovaginal candidiasis (thrush)
Cooke, G., Watson, C., Deckx, L., Pirotta, M., Smith, J., & van Driel, M. L. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009151.pub2 · Cited by 48
Metadata
- Authors
- Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., Edwards, L., Panzer, H., & Chu, T.-C.
- Affiliations
- Wayne State University (US)
- University of Pittsburgh (US)
- Hennepin County Medical Center (US)
- University of Washington (US)
- Johns Hopkins University (US)
- Pfizer (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-08-26
- Volume
- 351
- Issue
- 9
- Pages
- 876-883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2106311471
- Cited by
- 487
- References
- 21
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 17 · 2023: 26 · 2022: 22 · 2021: 21 · 2020: 22 · 2019: 15 · 2018: 28 · 2017: 30 · 2016: 26 · 2015: 29 · 2014: 23 · 2013: 24 · 2012: 23
- FWCI
- 11.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Urology › Urinary Tract Infections Management
- Keywords
- recurrent vulvovaginal candidiasis, fluconazole, maintenance therapy, Candida albicans, Candida glabrata, antifungal resistance, superinfection, recurrence prevention, clinical remission
- MeSH terms
- Administration, Oral, Adult, Antifungal Agents, Candida albicans, Candidiasis, Vulvovaginal, Double-Blind Method, Drug Administration Schedule, Female, Humans, Remission Induction, Time Factors, Vagina, Fluconazole, Logistic Models, Drug Resistance, Fungal, Candida glabrata, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
